Oral cancer is the sixth most common cause of death from cancer with an estimated 400，000 deaths worldwide and a low (50%) 5-year survival rate. The most common form of oral cancer is oral squamous cell carcinoma (OSCC). OSCC is highly inflammatory and invasive， and the degree of inflammation correlates with tumor aggressiveness. The G protein-coupled receptor protease-activated receptor-2 (PAR-2) plays a key role in inflammation. PAR-2 is activated via proteolytic cleavage by trypsin-like serine proteases， including kallikrein-5 (KLK5)， or by treatment with activating peptides. PAR-2 activation induces G protein-α-mediated signaling， mobilizing intracellular calcium and Nf-κB signaling， leading t... More
Oral cancer is the sixth most common cause of death from cancer with an estimated 400，000 deaths worldwide and a low (50%) 5-year survival rate. The most common form of oral cancer is oral squamous cell carcinoma (OSCC). OSCC is highly inflammatory and invasive， and the degree of inflammation correlates with tumor aggressiveness. The G protein-coupled receptor protease-activated receptor-2 (PAR-2) plays a key role in inflammation. PAR-2 is activated via proteolytic cleavage by trypsin-like serine proteases， including kallikrein-5 (KLK5)， or by treatment with activating peptides. PAR-2 activation induces G protein-α-mediated signaling， mobilizing intracellular calcium and Nf-κB signaling， leading to the increased expression of pro-inflammatory mRNAs. Little is known， however， about PAR-2 regulation of inflammation-related microRNAs. Here， we assess PAR-2 expression and function in OSCC cell lines and tissues. Stimulation of PAR-2 activates Nf-κB signaling， resulting in RelA nuclear translocation and enhanced expression of pro-inflammatory mRNAs. Concomitantly， suppression of the anti-inflammatory tumor suppressor microRNAs let-7d， miR-23b， and miR-200c was observed following PAR-2 stimulation. Analysis of orthotopic oral tumors generated by cells with reduced KLK5 expression showed smaller， less aggressive lesions with reduced inflammatory infiltrate relative to tumors generated by KLK5-expressing control cells. Together， these data support a model wherein KLK5-mediated PAR-2 activation regulates the expression of inflammation-associated mRNAs and microRNAs， thereby modulating progression of oral tumors.
